[ad_1]
NEW YORK – The Fourth International Conference on Cancer Immunotherapy organized by CRI-CIMT-EATI-AACR: Translating Science into Survival, will be held in New York from September 30 to October 30. 3, will present cutting-edge research studies from around the world that will attempt to answer urgent questions in the field of cancer immunotherapy in order to advance progress more quickly for patients.
Cancer immunotherapeutics work by releasing the power of the patient's immune system to fight cancer as it does to fight pathogens such as viruses and bacteria. The immune inhibitors of control points such as pembrolizumab and nivolumab, as well as CAR-T-Cell therapy, have revolutionized cancer care in recent years by producing dramatic and lasting responses in patients who previously had few Treatment options. However, such responses are observed only in a fraction of patients and many patients develop resistance to these treatments. It is necessary to continue research and innovation so that more patients can benefit from the promises of cancer immunotherapy.
"We have made tremendous progress in cancer immunotherapy over the past decade, the number of immunotherapeutic drugs has almost quadrupled, and the number of cancer types that can be treated with at least one immunotherapeutic drug. more than tripled, "said Elizabeth M., president of the AACR. Jaffee, MD, co-chair of this year's conference and deputy director of the John Smith Hopkins University Comprehensive Cancer Center Sidney Kimmel. "As research broadens our understanding of the immune system and its interaction with cancer cells, immunotherapy will progress a lot, with new treatment approaches that will increase the number of patients who will benefit."
A press luncheon will be held on Monday 1 October at 1 pm AND including experts in cancer immunotherapy who will discuss these areas of research interest and other topics of the meeting. Journalists interested in attending remotely can watch live on https://youtu.be/9G_ufP3LEjg.
Several presentations at the conference also address these issues.
Who reacts to immune checkpoint inhibitors and why?
Developing new approaches to identifying responders and non-responders to immune checkpoint inhibitors can help determine who should receive these drugs and who should receive alternative treatment.
A study using big data and genomic analysis to identify new patients likely to respond to immune checkpoint inhibitors is the abbreviated B085, "High Mutation Charge and Response to Immune Control Point Inhibitors in angiosarcomas of the scalp and face ", presented by Corrie Painter PhD, Broad Institute of MIT and Harvard during the B Poster Session on Tuesday, October 2.
What can be done to improve response rates and overcome resistance to immune checkpoint inhibitors?
Immune checkpoint inhibitors improve outcomes for only a subset of cancer patients, and many have their cancers stop responding to treatment. The following summaries are examples of work in progress to address these issues:
-Roberta Zappasodi, PhD, Sloan Kettering Memorial Cancer Center, will present the abstract A225 / PR1, "Mechanistic Rationale Combining GITR Agonism and Blocking PD-1 in Cancer Patients", during the session. poster presentation A and session 1: T-cell regulation and their response to cancer on Sunday, September 30th. This study examines a new combination therapy that could help fight resistance.
-Elizabeth Evans, PhD, of Vaccinex, Inc., will present summary A068 / PR10, "Reprogramming Myeloid Cells in TME with Pepinemab, First Semaphorin 4D Antibody, Improving Association Immunotherapy", during of the Poster Session A Sunday and Sept 30 and Session 5: New Combinations of Vaccines and Combinations on Tuesday, October 2nd. This preclinical research evaluates the mechanisms underlying the ability of a new treatment to enhance the activity of immune checkpoint inhibitors, these associations being investigated in several trials clinics.
-Stephen Schoenberger, PhD, La Jolla Institute of Allergy and Immunology, will present summary B090 / PR12, "Functional identification and therapeutic targeting of tumor neo-antigens", during the session. Display B and Session 6: Mutual Analysis and Prediction of Response to Immunotherapy, October 2. The technology described in this study could potentially help identify a broader range of tumor-specific neo-antigens, which is important for the development of personalized cancer vaccines and cellular immunotherapies.
In addition, Padmanee Sharma, MD, Ph.D., MD Anderson, University of Texas Cancer Center, will present a lecture entitled "From Clinic to Laboratory: Investigating Cancer," William B. Coley Award Winner distinguished research in immunology of tumors. mechanisms of response and resistance to immune treatment at checkpoints ", Sunday, September 30 at 2:15 pm ET.
What new immunotherapies are on the horizon for cancer patients?
In addition to immune checkpoint inhibitors and TAC cell therapy, researchers are studying other ways to release the immune system against cancer. These two summaries are examples of new approaches to cancer immunotherapy being tested in early phase clinical trials:
-Jay Berzofsky, MD, PhD, Vaccination Directorate, Cancer Research Center, National Cancer Institute, will present abstract A004, "Phase I clinical trial of HER2 cancer vaccine shows clinical benefit in 54% of evaluable patients ", September 30th. According to the results of these trials, treatment with an HER2-targeting therapeutic cancer vaccine had clinical benefits for several patients with HER2-positive metastatic cancer who had never previously been treated with a HER2-targeting therapeutic agent.
-Filip Janku, MD, Ph.D., MD Anderson Cancer Center of the University of Texas, will present his abstract A011, "In Vivo Clinical Trial of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients". patients with advanced solid tumors refractory to treatment: safety, activity and immune responses ", during Poster Session A on Sunday, September 30. This trial demonstrated that the use of bacterial spores of Clostridium novyi-NT in monotherapy injectable had manageable toxicities and showed early clinical efficacy in treatment-refractory patients with solid tumor malignancies.
The science program will include lectures from more than 50 industry leaders and will draw more than 1,200 participants from academia, industry and the advocacy community. A complete program is available here: http://www.cancerimmunotherapyconference.org/program-of-events/. All abstracts are available via the conference application: http://www.cancerimmunotherapyconference.org/abstracts/.
Source link
